
    
      Patients with all types of MS (Relapsing Remitting, Secondary Progressive, or Primary
      Progressive) are eligible to participate. Participants will undergo detailed cognitive
      assessment before initiating treatment and again after 90 days of treatment, to determine
      whether Caprylic Triglyceride demonstrates a benefit over placebo.

      Dosage: 40 gram packet orally once a day Duration of Treatment: 90 days

      Analyses: Interim analyses will be conducted after 72 subjects have completed the trial and
      objective STOP criteria for efficacy and futility have been defined in the protocol. Final
      analyses will be an intent-to-treat (ITT) analysis to evaluate each of the primary aims.
    
  